Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERU-111 in mCRPC
NCT03752099Phase 2Terminated
- Sponsor
- Veru Inc.
- Start
- Jan 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sabizabulin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Veru Inc.. Started Jan 2019; status: terminated.
02
Drugs
sabizabulin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03752099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03752099.